Core Viewpoint - The change in actual control of Zhejiang Apac Pharmaceutical Co., Ltd. marks a significant strategic transformation for the company, emphasizing innovation as the core driver for development in the context of profound changes in the pharmaceutical industry [1] Group 1: Control Change and Strategic Shift - Qiu Zhongxun has officially become the actual controller of Apac Pharmaceutical, indicating a major shift in the company's ownership structure and strategic direction [1] - The pharmaceutical industry in China is undergoing deep transformations, with a focus on innovation and the increasing pressure on traditional generic drug companies due to policies like volume-based procurement [1] Group 2: New Leadership and Industry Background - Qiu Zhongxun brings over 20 years of experience in the pharmaceutical industry and is the founder and chairman of Yaodou Technology, a leading pharmaceutical internet platform [2] - Under Qiu's leadership, Yaodou Technology has shown strong growth, with projected revenue exceeding 6 billion yuan in 2024 and a cumulative transaction scale of 65 billion yuan [2] Group 3: Fundraising and R&D Initiatives - Apac Pharmaceutical plans to issue up to 136,986,301 shares to raise no more than 700 million yuan, with all funds allocated for new drug research and development [3] - The funding will focus on three key areas: oncolytic virus drug development, long-acting and complex formulation platforms, and multiple innovative drug pipelines [3] Group 4: Dual-Driven Development Strategy - The company aims to establish a dual-driven model of "industrial resources + innovative R&D," optimizing its traditional generic drug business while increasing investment in innovative drug development [4] - This strategic upgrade is timely, as the innovative drug market is expected to grow significantly faster than the overall pharmaceutical market in the next three years [4] Group 5: Future Outlook - Apac Pharmaceutical plans to increase its R&D investment as a percentage of revenue to an industry-leading level within three years, leveraging both self-developed and introduced projects [5] - The extensive sales network and market resources from Yaodou Technology are expected to facilitate the rapid commercialization of Apac's innovative products [5] Group 6: Industry Expert Insights - Experts believe that with the dual drive of industrial capital and innovative R&D, Apac Pharmaceutical is poised to carve out a unique development path, enhancing existing business value while fostering long-term competitiveness [6] - The recent control change and strategic initiatives signify a new development phase for Apac Pharmaceutical, aiming for high-quality growth driven by innovation and supported by industrial resources [6]

Group 1 - The core point of the article is that Asia-Pacific Pharmaceutical announced the decision to dissolve its wholly-owned subsidiary, Wuhan Guanggu Asia-Pacific Pharmaceutical Co., Ltd., during the fifth meeting of the eighth board of directors held on October 13, 2025 [1] Group 2 - The decision to dissolve the subsidiary was formally approved in the board meeting [1] - The announcement was made on the evening of October 13 [1]

于2025年10月13日，星浩控股与上市公司签订附条件生效的《股份认购协议》。同时，上市公司控股股 东富邦集团及其全资子公司汉贵投资与星浩控股及其一致行动人星宸投资签署了《股份转让协议》;星 浩控股与其一致行动人星宸投资签署了《一致行动人协议》《表决权委托协议》。富邦集团及其全资子 公司汉贵投资通过协议转让方式将其合计持有的1.09亿股上市公司股票(占公司总股本的14.61%)转让给 星浩控股及其一致行动人星宸投资;上述股份转让交割后，星宸投资按照《一致行动人协议》约定与星 浩控股保持一致行动，以确保星浩控股对亚太药业的实际控制;星宸投资将其获得的4842.03万股上市公 司股票(占公司总股本的6.49%)对应的全部表决权、召集权、提名和提案权、参会权、监督建议权及除 收益权和股份转让等财产性权利之外的其他权利无条件、不可撤销地委托给星浩控股行使。上市公司的 控股股东变更为星浩控股，实际控制人变更为邱中勋先生。 此外，公司股票自2025年10月14日开市起复牌。 智通财经APP讯，亚太药业(002370.SZ)披露2025年度向特定对象发行股票预案，公司拟向浙江星浩控股 合伙企业(有限合伙)发行股票不超过1. ...

每经AI快讯，亚太药业（SZ 002370，收盘价：5.67元）10月13日晚间发布公告称，浙江亚太药业股份 有限公司于2025年9月26日收到控股股东宁波富邦控股集团有限公司及一致行动人上海汉贵投资管理有 限公司、实际控制人宋汉平、傅才、胡铮辉组成的管理团队通知，其正在筹划公司控制权变更事项，该 事项可能导致公司控股股东及实际控制人发生变更。鉴于相关事项处于筹划阶段，尚存在重大不确定 性，为保证公平信息披露，避免公司股价异常波动，维护广大投资者利益，经公司向深圳证券交易所申 请，公司股票自2025年9月29日（星期一）开市起停牌。 2025年10月13日，公司控股股东富邦集团及一致行动人汉贵投资与浙江星浩控股合伙企业（有限合伙） （以下简称"星浩控股"）及一致行动人浙江星宸股权投资合伙企业（有限合伙）（以下简称"星宸投 资"）签署了《股份转让协议》。富邦集团和汉贵投资拟通过协议转让方式转让公司14.62%股份，共计 108,945,566股。转让价格为8.26元/股，合计总金额为90,000.00万元，其中星浩控股受让富邦集团持有 的公司60,525,314股股份；星宸投资受让富邦集团、汉贵投资分别持有的公 ...

格隆汇10月13日丨亚太药业(002370.SZ)公布，基于公司未来发展战略规划，为优化企业组织架构，提 高公司运营管理效率，公司于2025年10月13日召开的第八届董事会第五次会议审议通过了《关于注销子 公司的议案》，同意注销全资子公司武汉光谷亚太药业有限公司（简称"光谷亚太药业"）。根据《深圳 证券交易所股票上市规则》《公司章程》等规定，本次注销子公司事项尚需提交公司股东大会审议，董 事会提请股东大会授权管理层或其授权人员办理本次子公司注销的相关事宜。 ...

Core Viewpoint - Asia Pacific Pharmaceutical (002370.SZ) plans to raise a total of up to RMB 700 million through a private placement of shares, with all proceeds allocated for new drug research and development projects [1] Group 1: Fundraising Details - The company intends to issue shares to a specific group, namely Zhejiang Xinghao Holding Partnership (Limited Partnership), which will subscribe to the shares in cash [1] - The agreement for share subscription was signed on October 13, 2025, with conditions for effectiveness [1] Group 2: Agreements and Partnerships - The controlling shareholder, Fubon Group, and its wholly-owned subsidiary, Hangu Investment, have signed a share transfer agreement with Xinghao Holding and its concerted party, Xingchen Investment [1] - Xinghao Holding and its concerted party, Xingchen Investment, have also signed a concerted action agreement and a voting rights entrustment agreement [1]

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ) has signed a share transfer agreement with its wholly-owned subsidiary Wuhan Guanggu Asia-Pacific Pharmaceutical Co., Ltd., transferring 100% equity of Shaoxing Yatai Pharmaceutical Technology Co., Ltd. for a nominal price of 1 yuan, as Yatai Pharmaceutical currently has negative net assets [1] Group 1 - The share transfer will change Yatai Pharmaceutical from a secondary wholly-owned subsidiary to a primary wholly-owned subsidiary of Asia-Pacific Pharmaceutical [1] - The company plans to optimize its organizational structure and improve operational management efficiency by liquidating Shaoxing Yatai Pharmaceutical Technology Co., Ltd. [1] - Management or authorized personnel will be granted the authority to handle the relevant matters for the subsidiary's liquidation [1]

Core Viewpoint - Asia-Pacific Pharmaceutical (002370.SZ) announced a share transfer agreement involving its controlling shareholder, Fubon Group, and its associates, transferring 14.62% of the company's shares to Zhejiang Xinghao Holdings and Zhejiang Xingchen Investment [1] Group 1: Share Transfer Details - Fubon Group and Han Gui Investment plan to transfer a total of 108,945,566 shares at a price of 8.26 yuan per share, amounting to a total of 900 million yuan [1] - Xinghao Holdings will acquire 60,525,314 shares from Fubon Group, while Xingchen Investment will acquire 28,894,686 shares and 19,525,566 shares from Fubon Group and Han Gui Investment, respectively [1] Group 2: Changes in Control - Following the completion of the share transfer, the controlling shareholder will change from Fubon Group to Xinghao Holdings [1] - The actual controller will shift from a management team consisting of Song Hanping, Fu Cai, and Hu Zhenghui to Qiu Zhongxun [1] Group 3: Stock Resumption - The company's stock (trading name: Asia-Pacific Pharmaceutical, stock code: 002370) will resume trading on October 14, 2025 [1]

Group 1 - The core point of the article is that Asia-Pacific Pharmaceutical (SZ 002370) announced a stock issuance plan to raise up to 700 million yuan for new drug research and development, with a specific issuance price of 5.11 yuan per share [1] - The stock issuance will involve a maximum of approximately 137 million shares, accounting for 18.37% of the company's total share capital before the issuance, and not exceeding 30% of the total share capital prior to the issuance [1] - As of the report, Asia-Pacific Pharmaceutical's market capitalization is 4.2 billion yuan, with 99.33% of its revenue coming from the pharmaceutical manufacturing sector for the first half of 2025 [1]

格隆汇10月13日丨亚太药业(002370.SZ)公布，公司控股股东富邦集团及一致行动人汉贵投资与浙江星 浩控股合伙企业（有限合伙）（简称"星浩控股"）及一致行动人浙江星宸股权投资合伙企业（有限合 伙）（简称"星宸投资"）签署了《股份转让协议》。富邦集团和汉贵投资拟通过协议转让方式转让公司 14.62%股份，共计108,945,566股。转让价格为8.26元/股，合计总金额为90,000.00万元，其中星浩控股 受让富邦集团持有的公司60,525,314股股份；星宸投资受让富邦集团、汉贵投资分别持有的公司 28,894,686股股份、19,525,566股股份。本次协议转让完成后，公司的控股股东将由富邦集团变更为星浩 控股，公司的实际控制人将由宋汉平、傅才、胡铮辉组成的管理团队变更为邱中勋。经公司申请，公司 股票（证券简称：亚太药业，证券代码：002370）自2025年10月14日开市起复牌。 ...